Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.